A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose PPIs.
Inclusion Criteria:
Each patient must meet all of the following criteria to be eligible for enrollment in this study:
Exclusion Criteria:
Patients who meet any of the following criteria will not be eligible to participate in the study:
NOTE: Other inclusion and exclusion criteria apply, per the study protocol.
Milwaukee, Wisconsin 53215, United States